Trailing-twelve-month (TTM) revenue is $100,000 with a year-over-year growth of (75.00%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-09-30 | $100,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q2 FY2026Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-10 |
| Q3 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-12 |
| Q4 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-28 |
| TTM revenue | $100,000 |
Current P/S: $67,844,155 market capitalization ÷ $100,000 TTM revenue = 678.44x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T16:05:14.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q4 FY2026 (2026-06-30): $0.00.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:08:03.884Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20172017-06-30 · USD | FY20182018-06-30 · USD | FY20192019-06-30 · USD | FY20202020-06-30 · USD | FY20212021-06-30 · USD | FY20262026-06-30 · USD |
|---|---|---|---|---|---|---|
| Collaborative Revenues | N/A | N/A | N/A | N/A | N/A | $100,000 |
| Grant | N/A | $44,000 |
$100,000
$100,000
(75.00%)
vs. $400,000 a year ago (TTM)
(46.91%)
5 Year compound annual growth rate
1 Year
(75.00%)
3 Year
N/A
5 Year
(46.91%)
10 Year
(20.14%)
15 Year
(10.41%)
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $100,000 | ($300,000) | (75.00%) |
| 2025 | $400,000 | +$175,000 | +77.78% |
| 2024 | $225,000 | ($1.66M) | (88.06%) |
| 2022 | $1.88M | ($487,000) | (20.54%) |
| 2021 | $2.37M | +$733,000 | +44.75% |
| 2020 |
TTM Growth
(75.00%)
3-Year CAGR
N/A
5-Year CAGR
(46.91%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T16:08:03.884Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| N/A |
| N/A |
| N/A |
| N/A |
| iBio CDMO | $123,000 | N/A | N/A | N/A | N/A | N/A |
|---|
| Ibio Cdmo | N/A | N/A | $0 | $92,000 | $1M | N/A |
|---|
| Ibio Inc | $271,000 | N/A | $2M | $2M | $1M | N/A |
|---|
| $1.64M |
| ($380,000) |
| (18.83%) |
| 2019 | $2.02M | +$1.57M | +354.50% |
| 2018 | $444,000 | +$50,000 | +12.69% |
| 2017 | $394,000 | ($554,000) | (58.44%) |
| 2016 | $948,000 | ($903,000) | (48.78%) |
